Vimarsana
Biggest News Aggregation in the World

Page 4 - Mark Joinnides News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Joinnides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Joinnides Today - Breaking & Trending Today

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease - Vimarsana News

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further cl...

Vaxxinity Reports First Quarter 2023 Financial Results and - Vimarsana News

Vaxxinity Reports First Quarter 2023 Financial Results and

CAPE CANAVERAL, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update - Vimarsana News

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

CAPE CANAVERAL, Fla., May 09, 2023 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first... | May 9, 2023

Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April - Vimarsana News

Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April

Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine... | March 28, 2023

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates - Vimarsana News

Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates

CAPE CANAVERAL, Fla., March 27, 2023 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth... | March 27, 2023